A Phase 2 Multicohort Trial to Further Characterize the Efficacy and Safety of Ciltacabtagene Autoleucel

Status

Recruiting

Phases

Phase 2

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2025-521975-30-00

Acronym

68284528MMY2012

Enrollment

Registered

2025-08-20

Start date

2025-10-03

Completion date

Unknown

Last updated

2025-10-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Newly Diagnosed Multiple Myeloma

Brief summary

MRD-negative CR at 12 months after cilta-cel infusion with a sensitivity of 10^-5

Interventions

DRUGCARVYKTI 3.2 × 10^6 – 1 × 10^8 cells dispersion for infusion

DRUGJNJ-68284528

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Design outcomes

Primary

Measure	Time frame
MRD-negative CR at 12 months after cilta-cel infusion with a sensitivity of 10^-5	—

Countries

Spain

Outcome results

None listed

Source: EU CTIS · Data processed: Feb 4, 2026